本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Seres Therapeutics, Inc.

5.09
+0.43009.23%
成交量:7.40萬
成交額:36.89萬
市值:5,112.80萬
市盈率:-2.11
高:5.15
開:4.67
低:4.67
收:4.66
52周最高:29.98
52周最低:4.32
股本:1,004.48萬
流通股本:883.47萬
量比:1.33
換手率:0.84%
股息:- -
股息率:- -
每股收益(TTM):-2.4137
每股收益(LYR):0.6400
淨資產收益率:-66.57%
總資產收益率:-39.85%
市淨率:1.48
市盈率(LYR):7.95

資料載入中...

公司資料

公司名字:
Seres Therapeutics, Inc.
交易所:
NASDAQ
成立時間:
2010
員工人數:
66
公司地址:
101 Cambridgepark Drive,Cambridge,Massachusetts,United States
郵編:
02140
電話:
傳真:
- -
簡介:
Seres Therapeutics, Inc.於2010年10月根據特拉華州法律註冊成立。該公司是一家臨床階段的生物製藥公司,專註於為醫療脆弱人群開發活體生物治療產品。其研發管線針對感染及炎症和免疫疾病,並利用首個獲得FDA批準的口服微生物組療法VOWST的開發經驗所建立的平台。

董事

名稱
職位
Richard N. Kender
Executive Chair and Interim Chief Executive Officer
Claire M. Fraser
Independent Director
Dennis A. Ausiello
Independent Director
Kurt C. Graves
Independent Director
Robert Rosiello
Independent Director
Stephen Berenson
Independent Director
Willard H. Dere
Independent Director
Eric D. Shaff
Director

股東

名稱
職位
Richard N. Kender
Executive Chair and Interim Chief Executive Officer
Kelly Brady
Executive Vice President, Chief Operating Officer
Marella Thorell
Executive Vice President, Chief Financial Officer
Matthew Henn
President and Chief Scientific Officer
Thomas J. DesRosier
Executive Vice President, Chief Legal Officer